Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × osimertinib × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21 Lung Neoplasms 11 Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Lymphoma 2 Hematologic Neoplasms 2 Breast Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Stage IB-IIIA Non-small Cell Lung Carcinoma 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non Small Cell Lung Cancer Metastatic 1 Multiple Endocrine Neoplasia Type 2a 1 Mesothelioma 1 Melanoma 1 Lethal Congenital Contracture Syndrome 2 1 Glioma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms 1

Interventions

Specimen Handling 11 Magnetic Resonance Spectroscopy 11 Cisplatin 8 pembrolizumab 7 Platinum 6 1,2-diaminocyclohexaneplatinum II citrate 6 Carboplatin 5 Biopsy 5 Radiotherapy, Intensity-Modulated 4 Radiotherapy 4 Paclitaxel 4 Cetuximab 4 cemiplimab 3 Radiation 3 (225)Ac-DOTA-c(RGDyK) 3 ipatasertib 2 cabozantinib 2 Taxes 2 Pemetrexed 2 Nivolumab 2 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2 zipalertinib 1 tislelizumab 1 repotrectinib 1 relatlimab 1 peposertib 1 osimertinib 1 lutetium Lu 177 dotatate 1 fludarabine phosphate 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05261399 2026-04-06

SAFFRON

AstraZeneca

Phase 3 Active not recruiting

Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡